InvestWiser

Annexin Pharmaceuticals AB

ANNXNasdaq StockholmHealthcareMarket value 76 m SEK
8.68SEK −4.6%
last day · Price as of 19 November 2026

The answer first

Does Annexin Pharmaceuticals beat the market?

No, Annexin Pharmaceuticals has not beaten the market over the last year.

Annexin Pharmaceuticals−65.3%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 22% of Nordic stocks

    • Quality99
    • Value4
    • Trend6

    No. 126 of 195 in healthcare

Max for seven days

Follow Annexin Pharmaceuticals with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Annexin Pharmaceuticals

From today, at a price of 8.68 SEK. Write why you follow Annexin Pharmaceuticals, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Annexin Pharmaceuticals

Your first answer is free, no account needed.

Do you own Annexin Pharmaceuticals, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Annexin Pharmaceuticals and a few more. Free, no card.

Past year against the exchange and Super Stock
Annexin Pharmaceuticals−65.3%Stockholm (OMXSGI)+17.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Annexin Pharmaceuticals has fallen 65.3% over the past year, including dividends.
  • Overall, Annexin Pharmaceuticals ranks better than 22% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 92.5%. The price is 97.6% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

22

Quality, value and trend together. Better than 22% of Nordic stocks.

No. 126 of 195 in healthcare

Quality99
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 7 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−341.2%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value4
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 169 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity5.2
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend6
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 167 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−34.2%
  • 6 months−33.5%
  • 9 months−55.5%
  • 12 months−65.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+3.8%
3 years, per year
−39.1%
5 years, per year
−35.6%
Year to date
−55.5%
Largest fall, 3 years
−92.5%
From a peak to the bottom
From the peak now
−97.6%
How far the price is from the peak
Volatility, 1 year
76.3%
How much the price swings over a year
Beta, 1 year
0.25
How much the price moves when the market moves

Return with dividends reinvested.

About Annexin Pharmaceuticals

Annexin Pharmaceuticals AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.

See the full analysis of Annexin Pharmaceuticals.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market